The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
出版年份 2019 全文链接
标题
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-08-05
DOI
10.1038/s41379-019-0339-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
- (2019) Keith M Kerr et al. LUNG CANCER
- Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
- (2018) H Wang et al. ANNALS OF ONCOLOGY
- Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations
- (2018) Bryce Noll et al. CANCER CYTOPATHOLOGY
- Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas
- (2018) Eleanor Russell-Goldman et al. CANCER CYTOPATHOLOGY
- Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients
- (2018) Marius Ilie et al. CANCER CYTOPATHOLOGY
- PD-L1 immunoexpression in matched biopsy and liquid based cytology samples of advanced stage non-small cell lung carcinomas
- (2018) Deepali Jain et al. CYTOPATHOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay
- (2018) Matthew Evans et al. PATHOLOGY & ONCOLOGY RESEARCH
- Assessment of Programmed Death–Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non–Small Cell Lung Carcinoma
- (2018) Andrea Hernandez et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer
- (2018) Peng Song et al. JOURNAL OF IMMUNOTHERAPY
- Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer
- (2018) Elisa Capizzi et al. LUNG CANCER
- Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features
- (2018) Linda Ye et al. MODERN PATHOLOGY
- Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
- (2018) Yasushi Yatabe et al. Journal of Thoracic Oncology
- The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking
- (2017) Birgit G Skov et al. HISTOPATHOLOGY
- Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
- (2017) Hironori Uruga et al. Journal of Thoracic Oncology
- Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
- (2017) Birgit G. Skov et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
- (2015) Satoru Kitazono et al. Clinical Lung Cancer
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population
- (2014) Birgit G Skov et al. APMIS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started